These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 27343406)

  • 1. Assessment of drug-induced arrhythmic risk using limit cycle and autocorrelation analysis of human iPSC-cardiomyocyte contractility.
    Kirby RJ; Qi F; Phatak S; Smith LH; Malany S
    Toxicol Appl Pharmacol; 2016 Aug; 305():250-258. PubMed ID: 27343406
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multi-parametric assessment of cardiomyocyte excitation-contraction coupling using impedance and field potential recording: A tool for cardiac safety assessment.
    Zhang X; Guo L; Zeng H; White SL; Furniss M; Balasubramanian B; Lis E; Lagrutta A; Sannajust F; Zhao LL; Xi B; Wang X; Davis M; Abassi YA
    J Pharmacol Toxicol Methods; 2016; 81():201-16. PubMed ID: 27282640
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An impedance-based approach using human iPSC-derived cardiomyocytes significantly improves in vitro prediction of in vivo cardiotox liabilities.
    Koci B; Luerman G; Duenbostell A; Kettenhofen R; Bohlen H; Coyle L; Knight B; Ku W; Volberg W; Woska JR; Brown MP
    Toxicol Appl Pharmacol; 2017 Aug; 329():121-127. PubMed ID: 28546047
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Moving beyond the comprehensive in vitro proarrhythmia assay: Use of human-induced pluripotent stem cell-derived cardiomyocytes to assess contractile effects associated with drug-induced structural cardiotoxicity.
    Yang X; Papoian T
    J Appl Toxicol; 2018 Sep; 38(9):1166-1176. PubMed ID: 29484688
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Refining the human iPSC-cardiomyocyte arrhythmic risk assessment model.
    Guo L; Coyle L; Abrams RM; Kemper R; Chiao ET; Kolaja KL
    Toxicol Sci; 2013 Dec; 136(2):581-94. PubMed ID: 24052561
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Screening drug-induced arrhythmia [corrected] using human induced pluripotent stem cell-derived cardiomyocytes and low-impedance microelectrode arrays.
    Navarrete EG; Liang P; Lan F; Sanchez-Freire V; Simmons C; Gong T; Sharma A; Burridge PW; Patlolla B; Lee AS; Wu H; Beygui RE; Wu SM; Robbins RC; Bers DM; Wu JC
    Circulation; 2013 Sep; 128(11 Suppl 1):S3-13. PubMed ID: 24030418
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cardiotoxicity Assessment of Drugs Using Human iPS Cell-Derived Cardiomyocytes: Toward Proarrhythmic Risk and Cardio-Oncology.
    Satsuka A; Kanda Y
    Curr Pharm Biotechnol; 2020; 21(9):765-772. PubMed ID: 31264543
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of cellular impedance measures of cardiomyocyte cultures for drug screening applications.
    Peters MF; Scott CW; Ochalski R; Dragan YP
    Assay Drug Dev Technol; 2012 Dec; 10(6):525-32. PubMed ID: 22574652
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Usefulness of cardiotoxicity assessment using calcium transient in human induced pluripotent stem cell-derived cardiomyocytes.
    Watanabe H; Honda Y; Deguchi J; Yamada T; Bando K
    J Toxicol Sci; 2017; 42(4):519-527. PubMed ID: 28717111
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An impedance-based cellular assay using human iPSC-derived cardiomyocytes to quantify modulators of cardiac contractility.
    Scott CW; Zhang X; Abi-Gerges N; Lamore SD; Abassi YA; Peters MF
    Toxicol Sci; 2014 Dec; 142(2):331-8. PubMed ID: 25237062
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comprehensive in vitro cardiac safety assessment using human stem cell technology: Overview of CSAHi HEART initiative.
    Takasuna K; Asakura K; Araki S; Ando H; Kazusa K; Kitaguchi T; Kunimatsu T; Suzuki S; Miyamoto N
    J Pharmacol Toxicol Methods; 2017; 83():42-54. PubMed ID: 27646297
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CSAHi study: Detection of drug-induced ion channel/receptor responses, QT prolongation, and arrhythmia using multi-electrode arrays in combination with human induced pluripotent stem cell-derived cardiomyocytes.
    Kitaguchi T; Moriyama Y; Taniguchi T; Maeda S; Ando H; Uda T; Otabe K; Oguchi M; Shimizu S; Saito H; Toratani A; Asayama M; Yamamoto W; Matsumoto E; Saji D; Ohnaka H; Miyamoto N
    J Pharmacol Toxicol Methods; 2017; 85():73-81. PubMed ID: 28163191
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety pharmacology studies using EFP and impedance.
    Obergrussberger A; Juhasz K; Thomas U; Stölzle-Feix S; Becker N; Dörr L; Beckler M; Bot C; George M; Fertig N
    J Pharmacol Toxicol Methods; 2016; 81():223-32. PubMed ID: 27084108
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of nefazodone-induced cardiotoxicity in human induced pluripotent stem cell-derived cardiomyocytes.
    Lee S; Lee HA; Choi SW; Kim SJ; Kim KS
    Toxicol Appl Pharmacol; 2016 Apr; 296():42-53. PubMed ID: 26821276
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Estimating the risk of drug-induced proarrhythmia using human induced pluripotent stem cell-derived cardiomyocytes.
    Guo L; Abrams RM; Babiarz JE; Cohen JD; Kameoka S; Sanders MJ; Chiao E; Kolaja KL
    Toxicol Sci; 2011 Sep; 123(1):281-9. PubMed ID: 21693436
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cross - site comparison of excitation-contraction coupling using impedance and field potential recordings in hiPSC cardiomyocytes.
    Bot CT; Juhasz K; Haeusermann F; Polonchuk L; Traebert M; Stoelzle-Feix S
    J Pharmacol Toxicol Methods; 2018; 93():46-58. PubMed ID: 29940218
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Use of Voltage Sensitive Dye di-4-ANEPPS and Video-Based Contractility Measurements to Assess Drug Effects on Excitation-Contraction Coupling in Human-Induced Pluripotent Stem Cell-Derived Cardiomyocytes.
    Hortigon-Vinagre MP; Zamora V; Burton FL; Smith GL
    J Cardiovasc Pharmacol; 2021 Mar; 77(3):280-290. PubMed ID: 33109927
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Human stem cell-derived cardiomyocytes in cellular impedance assays: bringing cardiotoxicity screening to the front line.
    Peters MF; Lamore SD; Guo L; Scott CW; Kolaja KL
    Cardiovasc Toxicol; 2015 Apr; 15(2):127-39. PubMed ID: 25134468
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Electrophysiological characteristics and pharmacological sensitivity of two lines of human induced pluripotent stem cell derived cardiomyocytes coming from two different suppliers.
    Goineau S; Castagné V
    J Pharmacol Toxicol Methods; 2018; 90():58-66. PubMed ID: 29274391
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Drug-induced functional cardiotoxicity screening in stem cell-derived human and mouse cardiomyocytes: effects of reference compounds.
    Himmel HM
    J Pharmacol Toxicol Methods; 2013; 68(1):97-111. PubMed ID: 23702537
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.